Fumarranol is a drug which acts as an inhibitor of the type 2 methionine aminopeptidase
enzymeMETAP2. It was derived by structural modification of the natural product
fumagillin. It was originally developed as an anti-
angiogenesis drug for the treatment of cancer,[1] but it was subsequently found to bind with high affinity to the METAP2 enzyme in
malaria parasites and has been investigated as a potential treatment for malaria.[2][3]
^Lu J, Chong CR, Hu X, Liu JO (September 2006). "Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo". Journal of Medicinal Chemistry. 49 (19): 5645–8.
doi:
10.1021/jm060559v.
PMID16970390.
^Chen X, Xie S, Bhat S, Kumar N, Shapiro TA, Liu JO (February 2009). "Fumagillin and fumarranol interact with P. falciparum methionine aminopeptidase 2 and inhibit malaria parasite growth in vitro and in vivo". Chemistry & Biology. 16 (2): 193–202.
doi:
10.1016/j.chembiol.2009.01.006.
PMID19246010.